Effect of mianserin, a potent anti-serotonin agent, on the isolated rat stomach fundus preparation.
D000109:Acetylcholine / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D002118:Calcium; D002746:Chlorpromazine / Q000494:pharmacology; D003533:Cyproheptadine / Q000494:pharmacology; D003913:Dextroamphetamine / Q000494:pharmacology; D003984:Dibenzazepines / Q000494:pharmacology*; D004147:Dioxins / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D066298:In Vitro Techniques; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D009020:Morphine / Q000037:antagonists & inhibitors; D009119:Muscle Contraction / Q000187:drug effects; D010643:Phenoxybenzamine / Q000037:antagonists & inhibitors; D010880:Piperidines / Q000494:pharmacology; D011433:Propranolol / Q000037:antagonists & inhibitors; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D011955:Receptors, Drug / Q000187:drug effects; D012601:Scopolamine / Q000037:antagonists & inhibitors; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists; D013270:Stomach / Q000187:drug effects*; D014363:Tryptamines / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D003984:Dibenzazepines; D004147:Dioxins; D010880:Piperidines; D011719:Pyrazines; D011955:Receptors, Drug; D012702:Serotonin Antagonists; D014363:Tryptamines; D010643:Phenoxybenzamine; D003533:Cyproheptadine; D012701:Serotonin; D009020:Morphine; D011433:Propranolol; D012601:Scopolamine; D000109:Acetylcholine; D002118:Calcium; D003913:Dextroamphetamine; D002746:Chlorpromazine; D008784:Methysergide